Functional polymorphisms in antioxidant genes in Hurthle cell thyroid neoplasm - an association of GPX1 polymorphism and recurrent Hurthle cell thyroid carcinoma
, , , and | Jul 19, 2016
About this article
Article Category: Research Article
Published Online: Jul 19, 2016
Page range: 289 - 296
Received: Jan 04, 2016
Accepted: May 02, 2016
DOI: https://doi.org/10.1515/raon-2016-0031
© 2016 Radiol Oncol
This content is free.
Association of clinical and demographic characteristics with Hurthle cell thyroid neoplasms, metastatic disease and recurrent disease
| HCTA+HCTN versus HCTC | Metastatic disease | Recurrent disease | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | p = p less than 0.05 was considered statistically significant | OR (95% CI) | p = p less than 0.05 was considered statistically significant | OR (95% CI) | p = p less than 0.05 was considered statistically significant | |
| Gender | 2.51 (1.03–6.12) | 0.043 | 2.08 (0.63–6.90) | 0.230 | 2.42 (0.70–8.37) | 0.163 |
| Age | 1.04 (1.01–1.06) | 0.004 | 1.07 (1.02–1.12) | 0.005 | 1.05 (1.01–1.10) | 0.026 |
| Tumor diameter | 1.05 (1.02–1.07) | < 0.001 | 1.09 (1.04–1.14) | < 0.001 | 1.04 (1.01–1.07) | 0.005 |
| Concomitant disease | 1.97 (0.90–4.34) | 0.092 | 0.83 (0.26–2.63) | 0.749 | 0.83 (0.26–2.63) | 0.523 |
Genotype frequencies in patients with Hurthle cell neoplasms
| Gene | Polymorphism | Genotype | All patients (%) | PHWE | HCTA+HCTN (%) | HCTC (%) |
|---|---|---|---|---|---|---|
| rs4880; c.47C>T; p.Val16Ala | CC | 26 (21.7) | 0.903 | 12 (17.9) | 14 (26.4) | |
| CT | 59 (49.2) | 34 (50.7) | 25 (47.2) | |||
| TT | 35 (29.2) | 21 (31.3) | 14 (26.4) | |||
| rs1001179; c.-262C>T; c.-262G>A | CC | 70 (58.3) | 0.907 | 35 (52.2) | 35 (66.0) | |
| CT | 43 (35.8) | 30 (44.8) | 13 (24.5) | |||
| TT | 7 (5.8) | 2 (3) | 5 (9.4) | |||
| rs1050450; c.599C>T; p.Pro200Leu | CC | 63 (52.1) | 0.424 | 35 (51.5) | 28 (52.8) | |
| CT | 51 (42.1) | 32 (47.1) | 19 (35.8) | |||
| TT | 7 (5.8) | 1 (1.5) | 6 (11.3) | |||
| rs1695; c.341C>T; p.Ile105Val | CC | 54 (44.6) | 0.653 | 28 (41.2) | 26 (49.1) | |
| CT | 52 (43.0) | 32 (47.1) | 20 (37.7) | |||
| TT | 15 (12.4) | 8 (11.8) | 7 (13.2) | |||
| rs1138272; c.313A>G; p.Ala114Val | AA | 103 (85.1) | 0.159 | 58 (85.3) | 45 (84.9) | |
| AG | 16 (13.2) | 8 (11.8) | 8 (15.1) | |||
| GG | 2 (1.7) | 2 (2.9) | 0 (0) | |||
| Gene deletion | Wild type | 55 (50.9) | / HWE could not be evaluated for GSTM1 and GSTT1 as we were not able to distinguish between carriers of one or two copies of each gene. | 33 (50.8) | 22 (51.2) | |
| Gene deletion | 53 (49.1) | 32 (49.2) | 21 (48.8) | |||
| Gene deletion | Wild type | 93 (86.1) | / HWE could not be evaluated for GSTM1 and GSTT1 as we were not able to distinguish between carriers of one or two copies of each gene. | 54 (83.1) | 39 (90.7) | |
| Gene deletion | 15 (13.9) | 11 (16.9) | 4 (9.3) |
Association of GSTP1 haplotypes and diagnosis of Hurthle cell neoplasm, presence of metastatic disease and occurrence of recurrent disease
| Haplotype | Estimated frequency | Diagnosis (HCTA+HCTN vs. HCTC) | Metastatic disease | Recurrent disease | |||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | p - p less than 0.05 was considered statistically significant | OR (95% CI) | pa | OR (95% CI) | p - p less than 0.05 was considered statistically significant | ||
| AC | 0.68 | Reference | Reference | Reference | |||
| GC | 0.25 | 0.88 (0.49–1.60) | 0.686 | 1.04 (0.38–2.86) | 0.935 | 0.45 (0.13–1.64) | 0.230 |
| GT | 0.07 | 0.83 (0.33–2.13) | 0.704 | 0.99 (0.21–4.72) | 0.988 | 028 (0.03–2.89) | 0.288 |
Association of SOD2, CAT, GPX1 and GST polymorphisms with diagnosis of Hurthle cell neoplasm, presence of metastatic disease and occurrence of recurrent disease
| Gene | Genotype | Diagnosis (HCTA+HCTN vs. HCTC) | Metastatic disease | Recurrent disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p = p less than 0.05 was considered statistically significant; | OR-adj = adjusted for tumor diameter | p-adj = adjusted for tumor diameter | OR (95% CI) | p = p less than 0.05 was considered statistically significant; | OR-adj = adjusted for tumor diameter | p-adj = adjusted for tumor diameter | OR (95% CI) | p = p less than 0.05 was considered statistically significant; | OR-adj = adjusted for tumor diameter | p-adj = adjusted for tumor diameter | ||
| CC | 0.61 | 0.264 | 0.65 | 0.373 | 1.12 | 0.856 | 0.72 | 0.706 | 1.11 | 0.878 | 0.82 | 0.788 | |
| rs4880 | CT+TT | (0.25–1.46) | (0.25–1.67) | (0.32–4.00) | (0.12–4.09) | (0.29–4.26) | (0.18–3.62) | ||||||
| CC | 0.56 | 0.129 | 0.81 | 0.600 | 0.34 | 0.102 | 0.57 | 0.499 | 1.25 | 0.721 | 2.95 | 0.155 | |
| rs1001179 | CT+TT | (0.27–1.18) | (0.36–1.81) | (0.09–1.24) | (0.11–2.91) | (0.37–4.25) | (0.66–13.1) | ||||||
| CC | 0.95 | 0.882 | 1.02 | 0.962 | 0.63 | 0.417 | 0.72 | 0.682 | 0.25 | 0.040 | 0.19 | 0.036 | |
| rs1050450 | CT+TT | (0.46–1.94) | (0.46–2.24) | (0.20–1.93) | (0.15–3.52) | (0.07–0.94) | (0.04–0.89) | ||||||
| CC | 0.73 | 0.388 | 0.82 | 0.628 | 1.30 | 0.646 | 2.40 | 0.291 | 0.46 | 0.202 | 0.49 | 0.300 | |
| rs1695 | CT+TT | (0.35–1.50) | (0.37–1.82) | (0.43–3.96) | (0.47–12.13) | (0.14–1.52) | (0.13–1.89) | ||||||
| AA | 1.03 | 0.952 | 1.15 | 0.800 | 0.99 | 0.988 | 1.24 | 0.836 | 0.29 | 0.261 | 0.24 | 0.244 | |
| rs1138272 | AG+GG | (0.38–2.83) | (0.39–3.45) | (0.21–4.67) | (0.17–9.19) | (0.03–2.54) | (0.02–2.64) | ||||||
| Wild type Gene deletion | 0.98 (0.46–2.13) | 0.968 | 0.91 (0.39–2.12) | 0.819 | 1.59 (0.47–5.39) | 0.456 | 1.40 (0.23–8.57) | 0.716 | 1.32 (0.38–4.64) | 0.666 | 1.24 (0.28–5.41) | 0.774 | |
| Wild type Gene deletion | 0.50 (0.15–1.70) | 0.269 | 0.44 (0.11–1.82) | 0.257 | 1.44 (0.18–11.29) | 0.730 | 0.83 (0.02–39.34) | 0.923 | 2.00 (0.25–15.85) | 0.512 | 1.42 (0.1–20.98) | 0.798 | |
Clinical and demographic characteristics of patients with Hurthle cell neoplasms
| HCTA + HCTN | HCTC | |
|---|---|---|
| Number [N] (%) | 68 (56.2) | 53 (43.8) |
| Median age [years] (range ) | 49.5 (38.5–57.8) | 62 (45.5–70.5) |
| Gender F/M [N] (%) | 58/10 (85.3/14.7) | 37/16 (69.8/30.2) |
| Median tumor diameter [mm] (range ) | 26.0 (16.0–34.8) | 40.0 (25.5–65.0) |
| Metastasis (%) | / | 20 (37.7) |
| Recurrence (%) | / | 16 (30.2) |
| Concomitant disease N (%) | 16 (23.5) | 20 (37.7) |
| Hashimoto thyroiditis | 11 (16.2) | 12 (22.6) |
| Diabetes mellitus | 1 (1.5) | 7 (13.2) |
| Graves’ disease | 2 (2.9) | 3 (5.7) |
| Non-thyroid Malignancy | 2 (2.9) | 2 (3.8) |